行情

CCXI

CCXI

ChemoCentryx
NASDAQ

实时行情|Nasdaq Last Sale

62.02
-1.37
-2.16%
盘后: 62.02 0 0.00% 16:57 01/15 EST
开盘
63.03
昨收
63.39
最高
63.88
最低
60.79
成交量
36.25万
成交额
--
52周最高
65.43
52周最低
30.72
市值
42.92亿
市盈率(TTM)
-91.9632
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
Diabetic Nephropathy Market 2021 Share, Size Global Manufactures, Consumption, Drivers, Top Leading Countries, Trends, Forces Analysis, Revenue, Challenges and Global Forecast to 2025
Jan 12, 2021 (The Expresswire) -- Global Diabetic Nephropathy Market Research Report focuses on market size, status and forecast 2020-2025, along with this...
The Express Wire · 4天前
每日生物技术脉搏:Ziopharm将在不良的临床试验结果中开始进行血液癌研究,Chemocentryx和Soligenix衰落
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 20)
Benzinga · 2020/12/22 12:45
ChemoCentryx和VFMCRP提供了Avacopan治疗C3肾小球病变的ACCOLADE试验的主要结果,包括改善的估计肾小球滤过率
As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment The change from baseline to Week 26 in C3
Benzinga · 2020/12/21 21:09
Recap: ChemoCentryx Q3 Earnings
Shares of ChemoCentryx (NASDAQ:CCXI) fell 8.59% in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share were down 59.09% year over year to ($0.35), which missed the estimate of ($0.31).Revenue of $5,085,000 declined by 51.94% from the same period last year, which missed the estimate of $10,700,000.Guidance ChemoCentryx hasn't issued any earnings guidance for the time being.ChemoCentryx hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: Nov 09, 2020View more earnings on CCXITime: 05:00 PMET Webcast URL: https://edge.media-server.com/mmc/p/ehp3weoiPrice Action Company's 52-week high was at $65.43Company's 52-week low was at $7.88Price action over last quarter: Up 8.05%Company Description ChemoCentryx Inc is a biopharmaceutical company involved in discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.See more from Benzinga * Click here for options trades from Benzinga * Earnings Outlook For ChemoCentryx * Benzinga's Top Upgrades, Downgrades For October 29, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 2020/11/09 22:01
投资者押注医疗保健股将成为分裂政府的大选赢家之一
The possibility of a divided government is transpiring and bringing relief to health related stocks
CNBC.com · 2020/11/07 16:34
ChemoCentryx Announces Plenary Session At ACR Convergence 2020 To Highlight Findings Of ADVOCATE Phase III Trial In ANCA-Associated Vasculitis
-- Study Showed Treatment with Avacopan Achieved Statistical Superiority in Sustaining Remission at 52 Weeks and Greater Improvement in Renal Function Compared to the
 Study Showed Treatment with Avacopan Achieved Statistical Superiority in Sustaining Remission at 52 Weeks and Greater Improvement in Renal Function Compared to the · 2020/11/06 13:33
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)
Benzinga · 2020/10/29 11:30
JP Morgan Downgrades ChemoCentryx to Neutral, Lowers Price Target to $60
JP Morgan analyst Anupam Rama downgrades ChemoCentryx (NASDAQ:CCXI) from Overweight to Neutral and lowers the price target from $63 to $60.
Benzinga · 2020/10/29 09:58
更多
财务预测
每股收益每股净资产每股现金流
实际值(美元)
预测值(美元)
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解CCXI最新的财务预测,通过CCXI每股收益,每股净资产,每股现金流等数据分析ChemoCentryx近期的经营情况,然后做出明智的投资选择。
分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测CCXI价格均价为80.63,最高价位119.00,最低价为60.00。
EPS
机构持股
总机构数: 272
机构持股: 5,669.46万
持股比例: 81.92%
总股本: 6,920.84万
类型机构数股数
增持
89
760.63万
建仓
73
-90.20万
减持
51
353.33万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
+0.43%
制药与医学研究
+0.21%
高管信息
Chairman/Chief Executive Officer/President/Director
Thomas Schall
Chief Financial Officer/Executive Vice President/Chief Administrative Officer/Secretary/IR Contact Officer
Susan Kanaya
Treasurer
Markus Cappel
Independent Director
Thomas Edwards
Independent Director
Joseph Feczko
Independent Director
Rita Jain
Independent Director
Henry McKinnell
Independent Director
Geoffrey Parker
Independent Director
James Tyree
  • 分红
  • 拆股
  • 内部人交易
暂无数据
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取
CCXI 简况
ChemoCentryx, Inc.(简称ChemoCentryx)是一家生物制药公司。该公司致力于发现、开发和商业化治疗孤儿与罕见疾病、自身免疫性疾病、炎症性疾病和癌症的口服疗法。该公司针对趋化系统,即包括趋化因子配体及其相关受体的分子网络,以及相关趋化受体从事业务。该公司的候选药物是多种靶向特定趋化因子或趋化受体的小分子,从而阻断由该特定受体驱动的负相关性炎症或抑制性应答,同时保持免疫系统其他部分的完整。该公司的产品包括针对孤儿与罕见疾病、免疫肿瘤学、慢性肾脏疾病和其他炎症与自身免疫性疾病的多个项目。
展开
热门股票
代码
价格
涨跌幅

微牛提供ChemoCentryx Inc(NASDAQ-CCXI)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CCXI股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CCXI股票基本功能。